The newborn screening market in Canada is expected to reach a projected revenue of US$ 38.8 million by 2033. A compound annual growth rate of 8.5% is expected of Canada newborn screening market from 2026 to 2033.
The Canada newborn screening market generated a revenue of USD 20.4 million in 2025 and is expected to reach USD 38.8 million by 2033.
The Canada market is expected to grow at a CAGR of 8.5% from 2026 to 2033.
In terms of segment, tandem mass spectrometry was the largest revenue generating technology in 2025.
Electrophoresis is the most lucrative technology segment registering the fastest growth during the forecast period.
Newborn screening market data book summary
Market revenue in 2025
USD 20.4 million
Market revenue in 2033
USD 38.8 million
Growth rate
8.5% (CAGR from 2026 to 2033)
Largest segment
Tandem mass spectrometry
Fastest growing segment
Electrophoresis
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Tandem Mass Spectrometry, Electrophoresis, Pulse Oximetry, Enzyme-based Assay, DNA Assays
Key market players worldwide
Bio-Rad Laboratories Inc, Agilent Technologies, Agilent Technologies Inc, Covidien, Masimo Corp, Waters Corp, Natus Medical, GE HealthCare Technologies Inc Common Stock, PerkinElmer, Danaher Corp
Other key industry trends
In terms of revenue, Canada accounted for 2.1% of the global newborn screening market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In North America, U.S. newborn screening market is projected to lead the regional market in terms of revenue in 2033.
Canada is the fastest growing regional market in North America and is projected to reach USD 38.8 million by 2033.
Unlike the extreme awareness levels witnessed in the U.S., Canada is still lagging in its efforts towards newborn screening program. Officially, Canada has no national standards set for screening of neonates and uses the ones established by the U.S. Mandated screening is applicable on only two conditions of those listed in the RUSP, which are congenital hypothyroidism and phenylketonuria.
However, in an attempt to change the scenario, Canadian Newborn and Child Screening Symposium held in May 2015 at Ontario highlighted the upcoming plans for the next five years. A few pointers of the plan are increasing involvement in innovation for newborn screening, collaborations, and tie-ups between industry representatives, clinicians, and market players and formation of uniform policies and standards.
Assisted regional growth can be witnessed over the next few years due to the market player PerkinElmer, which has commercially introduced the product range, EnLite, for Severe Combined Immunodeficiency (SCID) in December 2014
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Newborn Screening Market Outlook will help companies and investors design strategic landscapes.
Tandem Mass Spectrometry was the largest segment with a revenue share of 26.96% in 2025.
Horizon Databook has segmented the Canada newborn screening market based on tandem mass spectrometry, electrophoresis, pulse oximetry, enzyme-based assay, dna assays covering the revenue growth of each sub-segment from 2021 to 2033.
Unlike the extreme awareness levels witnessed in the U.S., Canada is still lagging in its efforts towards newborn screening program. Officially, Canada has no national standards set for screening of neonates and uses the ones established by the U.S. Mandated screening is applicable on only two conditions of those listed in the RUSP, which are congenital hypothyroidism and phenylketonuria.
However, in an attempt to change the scenario, Canadian Newborn and Child Screening Symposium held in May 2015 at Ontario highlighted the upcoming plans for the next five years. A few pointers of the plan are increasing involvement in innovation for newborn screening, collaborations, and tie-ups between industry representatives, clinicians, and market players and formation of uniform policies and standards.
Assisted regional growth can be witnessed over the next few years due to the market player PerkinElmer, which has commercially introduced the product range, EnLite, for Severe Combined Immunodeficiency (SCID) in December 2014
Canada Newborn Screening Market Technology Outlook (Revenue, USD Million , 2021-2033)
Tandem Mass Spectrometry
Pulse Oximetry
Enzyme-based Assay
DNA Assays
Electrophoresis
Others
Canada Newborn Screening Market Test Type Outlook (Revenue, USD Million , 2021-2033)
Dry Blood Spot Test
CCHD
Hearing Screen
Canada Newborn Screening Market Product Outlook (Revenue, USD Million , 2021-2033)
Instruments
Reagents
Reasons to subscribe to Newborn Screening Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Newborn Screening Market Outlook databook
Our clientele includes a mix of Newborn Screening Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Newborn Screening Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Newborn Screening Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.